newsfilter
← Latest News
GlobeNewswire·

Statera Biopharma, Inc., Announces Central Institutional Review Board Approval of Phase 3 Clinical Trial for Pediatric Crohn's Disease

STAT-201 is being developed as a novel, immune-modulation therapy for treating Crohn's Disease Phase 3 trial expected to begin in second quarter 2022 FORT COLLINS, Colo., Feb. 15, 2022 (GLOBE NEWSWIRE) -- Statera Biopharma, Inc. (NASDAQ:STAB), a